
Jessica DiGiacinto
Lead Editor at Forbes Health
Head of Content at MedShadow Foundation Blog
Articles
-
Nov 4, 2024 |
forbes.com | Jessica DiGiacinto |Nicole Gregory
Next Up In Medicare Information provided on Forbes Health is for educational purposes only. Your health and wellness is unique to you, and the products and services we review may not be right for your circumstances. We do not offer individual medical advice, diagnosis or treatment plans. For personal advice, please consult with a medical professional.
-
Nov 4, 2024 |
forbes.com | Alena Hall |Jessica Lester |Jessica DiGiacinto
Table of Contents {{ tocState.toggleTocShowMore ? 'Show more' : 'Show less' }} If you’re considering enrolling in a Medicare Advantage plan (also known as Medicare Part C) in Arkansas to meet your various health insurance needs, you’re not alone. According to recent Census data estimates, approximately 552,000 people ages 65 and older live in Arkansas, accounting for almost 18% of the state’s total population. Considering that Arkansas’s average life expectancy is nearly 72 years, securing...
-
Sep 30, 2024 |
medshadow.org | Jessica DiGiacinto
On September 26th, 2024, the FDA announced approval for Cobenfy (xanomeline and trospium chloride) the first novel schizophrenia treatment for adults in over 30 years. Early Cobenfy proponents find this new medication exciting because it may diminish some of the adverse side effects of currently available drugs. Right now, most antipsychotics that are prescribed for schizophrenia work by blocking dopamine, a chemical in the brain thought in hallucinations and delusions.
-
Sep 9, 2024 |
medshadow.org | Jessica DiGiacinto
What would you do if you were suffering from a terminal illness and you’d exhausted all medical options? If you answered “I’d try anything,” you’re not alone. Enacted in 1987, the FDA’s Expanded Access program (also referred to as “compassionate use”) allows patients with life-threatening illnesses to apply for and use drugs that are in development but not yet fully approved.
-
Jul 22, 2024 |
forbes.com | Nina Chamlou |Jessica DiGiacinto
Table of Contents {{ tocState.toggleTocShowMore ?
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →